The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
ALK,ROS 1 and NTRK 3 gene rearrangements in inflammatory myofibroblastic tumours
Abstract
Aims: The aim of this study was to elucidate the pathological features of inflammatory myofibroblastic tumour (IMT) with gene rearrangement other than ALK. Methods and results: We investigated anaplastic lymphoma kinase (ALK), ROS 1, ETV 6, NTRK 3 and RET in 36 cases of IMT by using immunohistochemical (IHC) staining, fluorescence in‐situ hybridization, and reverse transcription polymerase chain reaction (RT‐PCR). IHC staining showed ALK and ROS 1 to be positive in 22 of 36 (61.1%) and two of 36 (5.6%) cases, respectively. In one case with ROS 1 positivity, IHC staining showed cytoplasmic and dot‐like ROS 1 expression, and RT‐PCR showed the presence of the TFG–ROS 1 fusion transcript. Two cases of pulmonary IMT, in a 7‐year‐old patient and a 23‐year‐old patient, had ETV 6 rearrangement, and the presence of the ETV 6–NTRK 3 fusion transcript was confirmed in one case. These tumours were composed of hypocellular myxoid areas and highly cellular areas with rich plasmacytic infiltration; the histological features were different from those of infantile fibrosarcoma. RET rearrangement was not detected. Conclusions: These results suggest that a subset of ALK‐negative IMT s have rearrangement of ROS 1, ETV 6 or NTRK 3 as a possible oncogenic mechanism, and that the detection of these alterations may be of diagnostic value and helpful for determining promising therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Cited by
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
Amatu, A., Sartore-Bianchi, A., Bencardino, K., Pizzutilo, E. G., Tosi, F., & Siena, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz383 · Cited by 309
Recent Advances in Targeting ROS1 in Lung Cancer
Lin, J. J., & Shaw, A. T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.002 · Cited by 261
Metadata
- Authors
- Yamamoto, H., Yoshida, A., Taguchi, K., Kohashi, K., Hatanaka, Y., Yamashita, A., Mori, D., & Oda, Y.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2016-01-19
- Volume
- 69
- Issue
- 1
- Pages
- 72-83
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2194206428
- Cited by
- 208
- References
- 3
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.